RxDoctor Payments Data

Mary Allen, DO

Family Medicine · Louisville, KYNPI 1437710092

Payments from drug & device makers

$2,766in general payments, 2019–2025

Across 192 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$735
  • Novo Nordisk$452
  • Pfizer$226
  • AstraZeneca$162
  • GSK$160
  • Amgen$136
  • plus $895 from 25 others

What the payments were for

  • Food & beverage$2,75099%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,766 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$83,376
Medicare patients
227
Services billed
1,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$82,081
FarxigaDapagliflozin Propanediol52$62,669
OzempicSemaglutide50$60,761
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$49,749
EliquisApixaban60$49,596
MounjaroTirzepatide33$46,472
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$26,351
JanuviaSitagliptin Phosphate24$25,534
TrulicityDulaglutide18$21,710
MyrbetriqMirabegron14$12,349
Atorvastatin Calcium629$4,915
Breo ElliptaFluticasone/Vilanterol11$4,708
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,614
SymbicortBudesonide/Formoterol Fumarate12$3,117
Rosuvastatin Calcium235$2,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$162$92,13689 claims
Boehringer IngelheimJardiance$42$82,08156 claims
Lilly USA, LLCMounjaro, Trulicity$78$68,18151 claims
Novo NordiskOzempic$452$60,76150 claims
GSKTrelegy Ellipta, Breo Ellipta$160$54,45768 claims
PfizerEliquis$226$49,59660 claims
MerckJanuvia$22$25,53424 claims
Astellas Pharma US IncMyrbetriq$14$12,34914 claims
AbbVieSynthroid$735$1,74036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →